Decreased wakfeluness in human IGFBP3 transgenic mice. by Makoto Honda (102165)

“…<p>(A) Wakefulness is decreased in the second half of the dark/active period in human IGFBP3 transgenic mouse (h<i>IGFBP3</i> TG) versus wild type littermates (WT). …”

The influence of ghrelin on the thyroid-stimulating hormone (TSH)-induced (0.1 IU/L) mRNA expression of four thyroid components. by Maria Barington (4449151)

Diltiazem decreases the cell surface expression of ACE2. by Xinxin Wang (134010)

AIE decreases ChAT+IR in the basal forebrain in adulthood. by H. Scott Swartzwelder (473285)

“…<p>AIE decreases ChAT+IR in the Ch1 and Ch2 nuclei of the basal forebrain of adult rats (a). …”

VGB decreased activation of the mTOR pathway in vitro. by Bo Zhang (6559)

Expression of TSC-22 was decreased in human cancer tissue. by Cheol-Hee Yoon (147189)

Rab14 overexpression decreases phagocytosis of the malaria parasite. by Elsa Seixas (76018)

The thromboxane analogue, U-46619 decreased vessel diameter. by Simon C. Watkins (39900)

miR-155 decreases mycobacterial survival in macrophages. by Jinli Wang (469226)

VGB decreased activation of the mTOR pathway in vivo. by Bo Zhang (6559)

Decreased levels of cytokines and chemokines in the DLN of old mice. by Justin M. Richner (213025)

MGO decreases the levels of Hsc70 and Hsp90. by Carla Figueira Bento (359400)

HCV infection decreases MIN6 cell viability. by Qian Wang (32718)

GRIP1^-/- platelets do not have decreased velocity in ionophore-stimulated blood vessels. by Kristina L. Modjeski (3123072)

“…<p>A) GRIP1^-/- platelets do not have a decreased velocity in an ionophore-stimulated pinna vessel. …”

Accuracy decreases with response latency after stimulus offset. by Pamela Reinagel (282995)

Promoter activities of DNA-DRR genes decreased with DEC. by Hideaki Nakamura (402108)

Expression of lipid biosynthetic genes is decreased with polyamine depletion. by Yazmin E. Cruz-Pulido (20285238)

SFN pre-incubation decreases neutrophil respiratory burst. by Irundika H. K. Dias (425605)

Cellular input resistance is decreased during UP states. by Brendon O. Watson (268774)

HDAC inhibition by quisinostat synergizes with proteasome inhibition to decrease synovial sarcoma cell viability. by Aimée N. Laporte (3617987)

“…<p>(A) In all synovial sarcoma cell lines, but not HEK293T controls, the addition of 0.005 μM of bortezomib results in a downshift of approximately a full log of quisinostat, decreasing the amount of drug required to achieve the same effect as the HDAC inhibitor alone. …”